Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck vaqta (hepatitis A vaccine, legacy) — International sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, FY2023
61
Period ended Dec 31, 2023
Change on a year earlier
-21.8%
78 in FY2022
History
7 years
Since FY2017
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vaqta (hepatitis A vaccine, legacy) — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 61 | -21.8% | Form 10-K (filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 78 | -1.3% | Form 10-K (filed 2024-02-26) ↗ |
| FY2021 | Dec 31, 2021 | 79 | +17.9% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 67 | -38.0% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 108 | -3.6% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 112 | -9.7% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 124 | – | Form 10-K (filed 2020-02-26) ↗ |
Cite this data
StockData. (2026). Merck Vaqta (hepatitis A vaccine, legacy) — International sales ($M) ($M), annual FY2017–FY2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_vaqta_intl
See every metric in the Merck KPI table. Data updated Oct 26, 2026.